The interim research of Solidarity Therapeutics Trial coordinated by the World Health Organization (WHO) established that the use of antiviral drugs in the treatment of coronavirus cannot prevent the mortality from this disease as The New York Times reported.
Over 11,300 adults with Covid-19 participated in the WHO research in 405 hospitals of 30 countries. The partakers were provided with four medicines singly or in combination: remdesivir, hydroxychloroquine, lopinavir, interferon or interferon plus lopinavir.
The scientists concluded that remdesivir, hydroxychloroquine, lopinavir and interferon showed insignificant influence or showed any influence on 28-day mortality or intrahospital treatment of Covid-19 among hospitalized patients.
Finally, any medicines or combinations reduced mortality, the necessity of artificial lung ventilation or time spent in the hospital compared with patients without medical therapy.
The results of the research have not passed the reviewing and wait for consideration for publication in a medical journal. They are available as pre-print at medRxiv.
Meanwhile, the estimations continue of new antiviral drugs, immunomodulator and monoclonal antibodies against SARS COV-2.
As we reported, Ukraine is expected to receive Remdesivir for coronavirus treatment in a week. Patients with a severe form of the disease also need other drugs that have undergone appropriate clinical trials - immunoglobulins. The decision on their purchase will be made after the upcoming session of the government.